Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Topical anesthetic Stories

2013-10-10 08:28:50

Milestone Payment Related to Pliaglis Brazil Approval and Launch MISSISSAUGA, ON, Oct. 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the Company has been advised by its worldwide Pliaglis licensing partner, Galderma S.A. (Galderma), that Pliaglis has been approved for sale...

2013-09-05 08:28:32

Data Evaluating Heated Lidocaine/Tetracaine Patch for the Treatment of Acute Musculoskeletal Pain to be Presented MISSISSAUGA, ON, Sept. 5, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 announced today that researchers are presenting scientific data related to the heated lidocaine/tetracaine...

2013-07-10 16:26:37

MISSISSAUGA, ON and SOUDERTON, PA, July 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, and Galen US Incorporated, today announced that Nuvo and Nuvo's wholly owned subsidiary, ZARS Phama, Inc. and Galen have entered into a product acquisition and license agreement for Galen to acquire the exclusive rights to market and sell Nuvo's Synera patch throughout the...

2013-06-18 16:25:15

MISSISSAUGA, ON, June 18, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain announced today that, at its 2013 annual and special meeting of shareholders held in Mississauga, all nominees listed in the management proxy circular dated May 1, 2013 were elected, by a show of hands, as directors of the Company. The detailed results of the votes by proxy are as follows:...

2013-04-23 08:33:26

MISSISSAUGA, ON, April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.  Marketing licenses have been...

2013-04-19 08:25:31

Data Evaluating Synera(®) for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON, April 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera(®) (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22(nd) Annual Meeting of the American Medical Society for Sports Medicine...

2012-10-22 07:29:00

MISSISSAUGA, ON, Oct. 22, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Pliaglis® (lidocaine/tetracaine) 7%/7% Cream.  Nuvo has licensed worldwide...

2012-04-05 10:24:27

OTTAWA, April 5, 2012 /PRNewswire/ - Health Canada is informing Canadians that it has requested companies to add new risk statements to the packaging and labelling of licensed benzocaine products. In April 2011, Health Canada reminded Canadians of certain health risks associated with benzocaine products, including a very rare but serious blood condition known as methemoglobinemia that can affect sensitive individuals. The new statements are intended to further raise awareness of these...

2011-08-09 00:00:30

Absorption Pharmaceuticals' new corporate name aligns with its core technology - transdermal absorption of pharmaceutical agents. PROMESCENT, Absorption Pharmaceuticals' topical spray for premature ejaculation, enables users to quickly deliver controllable amounts of lidocaine to the dermis and subcutis/hypodermis in order to reduce senstivity of the penis and delay ejaculation. (PRWEB) August 07, 2011 The developers of the leading over-the-counter topical treatment for premature...

2009-07-10 13:15:53

Over-the-counter sport creams and heat gels are unproven and may do no more than rubbing your skin with saliva, a British biochemist said. The point is, you go to any pharmacy and find tons of these things, but they don't work, Andrew Moore, a biochemist at the University of Oxford, said. I wouldn't waste the money. You might as well rub your skin with a bit of spit. Moore's team reviewed studies of rub-on and spray-on preparations containing one or more salicylates. Aspirin, for example, is...